Abstract 1019P
Background
The efficacy of immune checkpoint inhibitors (ICIs) in SMARCA4 mutant non-small cell lung cancer (NSCLC) is limited. CD8+ T cell exhaustion plays an important role in damaging anti-tumor immunity, but the molecular mechanisms remain unclear.
Methods
We compared the survival difference between patients with SMARCA4 mutation and wild type. The RNA sequencing of CD8+T cells sorted from tumor tissues was performed. The SMARCA4 mutant-H1299 cells were implanted into the left flank of the NSG mice. 2×107 human PBMCs were separated and injected intravenously into NSG mice to establish humanized NSG mouse models. Anti-PD-1 of Bispecific PD1-IL2 antibody were given intraperitoneally. The frequencies and phenotypes of CD8+T cells in mouse spleens and blood were detected by flow cytometry while those in tumor tissues were determined by multiplex immunofluorescence (mIF). The mIF staining was performed to validate differences of CD8+ T cells exhaustion phenotype between SMARCA4 mutant and wild-type patient tissues.
Results
Treatment with ICIs could not improve outcomes in patients with SMARCA4 mutations (P = 0.754). The analysis of RNA sequencing showed that the production of interleukin-2 (IL-2) was significantly reduced in CD8+T cells of SMARCA4 mutant Lewis lung carcinoma (P < 0.001). The analysis of mIF revealed that the infiltration of PD1+CD8+, LAG3+CD8+, TIM3+CD8+ T cells increased in SMARCA4 mutant tumor tissues. We found that a high level of IL-2 leads to the persistent activation of STAT5 in CD8+ T cells. Bispecific PD1-IL2 antibody enhanced anti-tumor immunity and suppressed tumor progression by reversing CD8+T cells exhaustion.
Conclusions
The PD1-IL2 bispecific antibody could reverse CD8+T cell exhaustion to enhance anti-tumor immunity in SMARCA4 mutant NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H. Wang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1025P - Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers
Presenter: Santeri Pakola
Session: Poster session 03
1026P - Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster session 03
1027P - First results for intravenous (IV) VSV-GP (BI 1831169) in patients (pts) with advanced solid tumors from the 1456-0001 study
Presenter: Marc Oliva Bernal
Session: Poster session 03
1028P - A phase I study of personalized KSX01-TCRT therapy for advanced solid tumor and its mechanisms
Presenter: Shuhang Wang
Session: Poster session 03
Resources:
Abstract
1029P - Preclinical development of TCR-modified T cell therapies against mutated KRAS
Presenter: Hugh Salter
Session: Poster session 03
1030P - Survival rates in high-risk neuroblastoma patients undergoing anti-GD2 immunotherapy: A single arm meta-analysis and systemic review
Presenter: Lorena Escalante Romero
Session: Poster session 03
1032P - Tumor-infiltrating lymphocytes with inducible membrane-tethered IL-12 cultured in optimized media exhibits superior anti-tumor activity
Presenter: Patrick Innamarato
Session: Poster session 03
1033P - Anti-tumor efficacy and safety of conditionally activated armored CAR-T cells against gastrointestinal tumors
Presenter: Zhihong Huang
Session: Poster session 03
1034P - Preclinical development of genetically modified tumor-infiltrating lymphocytes using biopsy samples from liver cancer patients
Presenter: Mingyu Liu
Session: Poster session 03
1035P - A new IL-6 inducing mechanism in cancer with new therapeutic possibilities
Presenter: Leif Håkansson
Session: Poster session 03